Page 205 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Fluoropyrimidine dosages in chemoradiation therapy
Conclusions
Our study is the first to show that DPYD variant allele carriers have an increased risk of severe toxicity when treated with standard dosages in CRT, indicating that dose reductions are necessary in these patients as well. The present study provides the only evidence at this time, and based on these data we advise that fluoropyrimidine dose reductions should also be applied in DPYD variant allele carriers who will start CRT to prevent severe fluoropyrimidine-induced toxicity.
7
203